NCT07200583 2025-11-18
PAIA-Haplo
Fujian Medical University
Completed
Clinical Trials
10 trialsNCT03545035 2022-05-12
LLC178
Gruppo Italiano Malattie EMatologiche dell'Adulto
Completed
NCT03289182 2021-01-11
An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)
Hoffmann-La Roche
Completed
NCT02491398 2020-10-06
LLC1315
Gruppo Italiano Malattie EMatologiche dell'Adulto
Completed
NCT03582098 2019-04-12
RETRO-idel
Gilead Sciences
Completed
NCT01178086 2018-10-05
A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
Hoffmann-La Roche
Completed
NCT01609023 2018-06-26
CaLLypso
Hoffmann-La Roche
Completed
NCT01224093 2016-11-02
An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)
Hoffmann-La Roche
Completed
NCT01072240 2016-11-01
An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Completed
NCT02156726 2014-06-05
Q-lite
Czech CLL Study Group
Unknown